Rasio utang jangka cendhak marang ekuitas: Jupiter Neurosciences Inc (JUNS)

Jupiter Neurosciences Inc (JUNS) is a biotech developer of migraine and dementia treatments utilizing an innovative method for delivering resveratrol to the brain. However, the company faces significant uncertainty due to potential research failures and a shortage of funds. The current metric stands at 0.00. Serving as a valuation tool, this price chart illustrates the financial condition of the firm, which created a unique CNS treatment system with the drug Jotrol.

For Jupiter Neurosciences Inc (JUNS), whose R&D risks and operating losses are already priced in by the market, this indicator determines the degree of liquidity dependence on short-term borrowings relative to equity. By analyzing the chart of the short-term loan-to-equity ratio on GURU.Markets, an investor assesses the coverage of net assets by liabilities under one year, which is critical when awaiting long-term results from clinical trials of innovative molecules.